logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience drums up over US$2 million from private placement to boost its DehydraTECH technology

A portion of the funds will be used for the group's human pilot study on DehydraTECH's ability to boost the oral bioavailability of antiviral drugs

Lexaria Bioscience Corp. - Lexaria Bioscience drums up over US$2 million private placement
Lexaria said the rest of the money will drive the application process for a senior US exchange listing application, and for working capital

Lexaria Bioscience Corp (CSE:LXX) (OTCQX:LXRP), a global innovator in drug delivery platforms, has struck definitive agreements with qualified investors for the sale of 8,978,260 shares and warrants via a private placement to drum up proceeds of over US$2 million to boost its flagship DehydraTECH technology.

The company said the shares are being issued at a price of US$0.23 each, with the warrants immediately exercisable at a price of US$0.35 per share with a five-year term until expiry. The transaction is anticipated to close on May 6, subject to customary closing conditions, it added.

READ: Lexaria Bioscience says close to winning new patent for its flagship DehydraTECH technology

The Kelowna, British Columbia-based company said a portion of the funds will be used for completing a human pilot study researching the effectiveness of DehydraTECH to “enhance the oral bioavailability of certain antiviral drugs” with the potential of combatting the coronavirus (COVID-19) and other infectious diseases.

The rest of the money will drive the application process for a senior US exchange listing application, and for working capital, the company added.

The Special Equities Group, a division of Bradley Woods & Company Ltd. (BCW), is acting as the exclusive placement agent for the offering. Lexaria will pay US$154,199.90 and issue 658,087 warrants to BWC, or their nominee, in connection with the investment by investors of an aggregate 8,226,086 shares with associated warrants. The broker warrants have the same exercise terms and expiry date as the warrants.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Quick facts: Lexaria Bioscience Corp.

Price: 0.53 CAD

CSE:LXX
Market: CSE
Market Cap: $47.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Lexaria Bio Science and partner Altria complete Phase One of the development...

Lexaria BioScience (OTCQX: LXRP- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive Vancouver with news the company has seen their Phase One research and development program of oral forms of nicotine delivery finish with Altria Ventures. Bunka says everything went as planned and...

3 weeks, 3 days ago

2 min read